Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | CD69 | Q07108 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25751787 | 1.00 | ALDH1A1 (0.62) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL24239542 | 1.00 | ALDH1A1 (0.62) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL22021019 | 1.00 | ALDH1A1 (0.62) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL25446681 | 1.00 | ALDH1A1 (0.62) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL24004407 | 1.00 | ALDH1A1 (0.62) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL24004417 | 1.00 | ALDH1A1 (0.62) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL24239885 | 1.00 | ALDH1A1 (0.62) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL23692740 | 1.00 | ALDH1A1 (0.62) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL20713635 | 1.00 | ALDH1A1 (0.62) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL25494615 | 1.00 | ALDH1A1 (0.62) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20230220384-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-07-13 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230174459-A1 | LIPID CONTAINING FORMULATIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-06-08 | — | — | US | disclosed |
| US-20220195436-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF C3 IN A CELL | SILENCE THERAPEUTICS GMBH (DE) | 2022-06-23 | — | — | US | disclosed |
| US-20210347826-A1 | CYCLIC PEPTIDE COMPOUNDS AND METHODS OF USE THEREOF | MODULATION THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-20210228615-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2021-07-29 | — | — | US | disclosed |
| US-20210198305-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | PFIZER INC. | 2021-07-01 | — | — | US | disclosed |
| US-10905702-B2 | Inhibition of galectin 3 binding to the airway epithelial surface to treat or prevent septic shock resulting from influenza and subsequent pneumococcal pneumonia infection | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200361854-A1 | LIPID CONTAINING FORMULATIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-11-19 | — | — | US | disclosed |
| US-20200190515-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-06-18 | — | — | US | disclosed |
| US-20200157545-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-05-21 | — | — | US | disclosed |
| US-20190142853-A1 | Inhibition of Galectin 3 Binding to the Airway Epithelial Surface to Treat or Prevent Septic Shock Resulting From Influenza and Subsequent Pneumococcal Pneumonia Infection | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-05-16 | — | — | US | disclosed |
| US-20180065918-A1 | LIPID CONTAINING FORMULATIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-03-08 | — | — | US | disclosed |
| US-9663449-B2 | — | — | 2017-05-30 | — | — | US | disclosed |
| US-8642076-B2 | Lipid containing formulations | TEKMIRA PHARMACEUTICALS CORPORATION | 2014-02-04 | — | — | US | disclosed |
| US-20120046478-A1 | LIPID CONTAINING FORMULATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347826-A1 | CYCLIC PEPTIDE COMPOUNDS AND METHODS OF USE THEREOF | VIP, IAPP, SCTR | ALDH1A1 4324/4885THRB 1910/4885MAPK1 3238/4885 |
| US-20200190515-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | ALDH1A1 3065/4885THRB 4436/4885MAPK1 4496/4885 |
| US-20200361854-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | ALDH1A1 3971/4885THRB 4029/4885MAPK1 4789/4885 |
| US-20180065918-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | ALDH1A1 3971/4885THRB 4029/4885MAPK1 4789/4885 |
| US-20210228615-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | SMN1; SMN2, RBM17, RBM22 | ALDH1A1 2965/4885THRB 4657/4885MAPK1 4806/4885 |
| US-20230174459-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | ALDH1A1 3971/4885THRB 4029/4885MAPK1 4789/4885 |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | ALDH1A1 1901/4885THRB 4264/4885MAPK1 3843/4885 |
| US-20200157545-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | ALDH1A1 1745/4885THRB 4154/4885MAPK1 4321/4885 |
| US-20210198305-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, NSUN3 | ALDH1A1 2830/4885THRB 4174/4885MAPK1 4489/4885 |
| US-20190142853-A1 | Inhibition of Galectin 3 Binding to the Airway Epithelial Surface to Treat or Prevent Septic Shock Resulting From Influenza and Subsequent Pneumococcal Pneumonia Infection | LGALS3, LGALS3BP, LGALS1 | ALDH1A1 4171/4885THRB 2240/4885MAPK1 1448/4885 |
| US-20120046478-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | ALDH1A1 3971/4885THRB 4029/4885MAPK1 4789/4885 |
| US-10905702-B2 | Inhibition of galectin 3 binding to the airway epithelial surface to treat or prevent septic shock resulting from influenza and subsequent pneumococcal pneumonia infection | LGALS3, LGALS3BP, LGALS1 | ALDH1A1 4171/4885THRB 2240/4885MAPK1 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.